Bobby Graham Reporting from Washington, DC USA – At The Annual Alzheimer’s Association International Conference ( AAIC )
Do You Have A Chance At Getting Alzheimer's - Genomics Science Tells US:
Washington, DC ( AP )----- Barron’s Medical Journal has made it to Washington, DC for The Annual Alzheimer’s Association International Conference . The Biotech And Clinical Trial communities are all a buzz because on Wednesday of this week we are looking for the announcement of Aducanumab.
Aducanumab is the given USAN and INN name for a biopharmaceutical, the human monoclonal antibody and drug candidate BIIB0307 designed for treatment of Alzheimer's disease. 
This Drug has come at a great time and Mary Holland of Austin, Texas can live a long memorable life.
This Drug has come at a great time and Mary Holland of Austin, Texas can live a long memorable life.
A year-long study of 166 patients with a mild form of the disease showed that Biogen’s drug significantly reduced the build-up of plaque 
and delayed the onset of cognitive decline, according to data published on Friday at a medical conference in Nice, France.
and delayed the onset of cognitive decline, according to data published on Friday at a medical conference in Nice, France.
Shares in Biogen, which have risen about 28 per cent so far this year in anticipation of the data, jumped by 7 per cent in New York trading, while other companies with similar drugs also gained, including Eli Lilly, up 2.4 per cent, and Sanofi, which added 1.6 per cent. Biogen’s market value has risen by $45bn to nearly $110bn in a little over a year. However, analysts and physicians voiced concerns over the drug’s safety, with a quarter of patients on the highest dose discontinuing treatment due to adverse effects, including swelling on the brain.
Brought To You By kuhl-linscomb 
Drug companies have trialled similar drugs for years with disappointing results, but the industry has pressed ahead because the commercial opportunity is huge: there are more than 25m Alzheimer’s sufferers globally and 5m in the US, the vast majority of whom do not respond to existing treatments.
Drug companies have trialled similar drugs for years with disappointing results, but the industry has pressed ahead because the commercial opportunity is huge: there are more than 25m Alzheimer’s sufferers globally and 5m in the US, the vast majority of whom do not respond to existing treatments.
Biogen and its partner Neurimmune developed the drug by cloning the memory cells of people in their 90s who had “super cognitive function” despite their age, as well as people who had Alzheimer’s that was progressing at an unusually slow rate.
After years of Gennxeix Biotech Inc Researching Genomics and how to commercialize the science. We went back to visit with Rose Conrad Chief Executive Office of Gennxeix Biotech to discuss what is next in the pipeline for genomic Science in the next four years. Ms Conrad says a great example of the power of genomics was publicized in the New England Journal Of Medicine on November 14, 2014. The Gene TREM2. The TREM2 gene provides instructions for making a protein called triggering receptor expressed on myeloid cells 2. As its name suggests, this protein is made in myeloid cells, which are cells produced in bone marrow. 
The TREM2 protein is found on the cell surface, where it interacts with the protein produced from the TYROBP gene. The TREM2 and TYROBP proteins form a complex that transmits chemical signals to activate the cell. When the gene is not mutated, white blood cells in the brain spring into action, gobbling up and eliminating the plaque-forming toxic protein, beta amyloid. As a result, Alzheimer’s can be staved off or averted. But when the gene is mutated, the brain’s white blood cells are hobbled, making them less effective in their attack on beta amyloid.
The TREM2 protein is found on the cell surface, where it interacts with the protein produced from the TYROBP gene. The TREM2 and TYROBP proteins form a complex that transmits chemical signals to activate the cell. When the gene is not mutated, white blood cells in the brain spring into action, gobbling up and eliminating the plaque-forming toxic protein, beta amyloid. As a result, Alzheimer’s can be staved off or averted. But when the gene is mutated, the brain’s white blood cells are hobbled, making them less effective in their attack on beta amyloid.
People with the mutated gene have a threefold to fivefold increase in the likelihood of developing Alzheimer’s disease in old age. Conrad says If The Mom And The Dad Has Gene Trem2 ....The Child has a 89% Chance Of Getting Alzheimer's
Days after the 2012 Elections Electing President Obama Genomics is leading the way in a new discovery TREM2 Triggering receptor expressed on myeloid cells 2 is a protein that in humans is encoded by the TREM2 gene. The New Leading Technology To Cure Breast Cancer is also here according to Rose Conrad Ph.D. CEO GenNxeix Inc Nanoparticles and Semi Conductors GenNxeix Biotech Conrad explains: Quantum dots (QDs), also known as semiconducting nanoparticles, are promising zero‐dimensional advanced materials because of their nanoscale size and because they can be engineered to suit particular applications such as nonlinear optical devices (NLO), electro‐optical devices, and computing applications. QDs can be joined to polymers in order to produce nanocomposites which can be considered a scientific revolution of the 21st century.
One of the fastest moving and most exciting interfaces of nanotechnology is the use of QDs in medicine, cell and molecular biology. Recent advances in nanomaterials have produced a new class of markers and probes by conjugating semiconductor QDs with biomolecules that have affinities for binding with selected biological structures. The nanoscale of QDs ensures that they do not scatter light at visible or longer wavelengths, which is important in order to minimize optical losses in practical applications. Moreover, at this scale, quantum confinement and surface effects become very important and therefore manipulation of the dot diameter or modification of its surface allows the properties of the dot to be controlled. Quantum confinement affects the absorption and emission of photons from the dot. Thus, the absorption edge of a material can be tuned by control of the particle size. Nanocomposite systems for nanomedicine and bioengineering applications Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer. GenNxeix 
scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles).
scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles).
The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of
benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells Miniaturization will allow the tools for many different tests to be situated together on the same small device.
benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells Miniaturization will allow the tools for many different tests to be situated together on the same small device.
Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously. Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact. A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer. GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine.
No comments:
Post a Comment